ADVA
4.3.2021 09:02:10 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that VicTrack is building its new Transport and Government Secure Network (TGSN) on the ADVA FSP 3000 . The infrastructure enables railway operators to harness next-generation signaling technologies and provides high-speed connectivity for government agencies. Carrying services at speeds up to 100Gbit/s throughout the Australian state of Victoria, the flexible and fully redundant ROADM network also empowers VicTrack to offer highly reliable and cost-efficient wholesale services at 10Gbit/s and 100Gbit/s. What’s more, the FSP 3000 creates a modular network architecture, which is scalable and ready to support future transport innovation. ADVA’s team is also providing a comprehensive range of professional services from network design to ongoing training and support.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210304005026/en/
“Upgrading our backbone network with ADVA’s FSP 3000 technology enables us to keep pace with Victoria’s growing transport needs. Our new high-capacity infrastructure empowers us to support mission-critical rail operations, including operational communications, signaling, and video surveillance. And, with so much extra capacity, we can now offer carrier-grade wholesale services to other service providers,” said Andrew Peel, group manager commercial, telecommunications group, VicTrack. “We’re also excited by the platform’s inbuilt scalability. With a solution ready to expand to 600Gbit/s, we can plan to exploit new network technologies as they become available and expand services according to demand. Our customers and stakeholders will reap the benefits of this next-gen optical network for many years to come.”
Built on ADVA’s FSP 3000 platform, VicTrack’s TGSN is initially a 45-node meshed architecture with links across metro and regional Victoria. Featuring 96 channel filters, the new infrastructure provides a flexible mix of 10Gbit/s and 100Gbit/s services as well as any-to-any connectivity for seamless, simple and secure communication. Designed for scale and bandwidth optimization, ADVA’s FSP 3000 ensures VicTrack’s new TGSN infrastructure meets stringent density and energy demands. VicTrack is also utilizing ADVA’s Ensemble Controller service management solution. With its intuitive web-based user interface, it provides agile control of the ROADM layer and opens the door to automated network management.
“With the scale and openness of our FSP 3000 solution, VicTrack can be confident that it will have a highly efficient and secure transport system ready for emerging challenges and technologies for many years to come. The new TGSN network will provide vital opportunities for rail operators, government agencies and businesses across the state of Victoria. With its speed, flexibility and increased reliability, it will enable users to find new efficiencies and leverage the latest innovation,” commented Erik Lindberg, VP, sales, APAC, ADVA. “Throughout this deployment, we’ve given VicTrack’s team our close support. And, by taking advantage of our professional services, they’re ensuring that their stakeholders receive consistent quality of experience with a network running at peak performance all along its lifecycle.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210304005026/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom